Issuance details of new stock acquisition rights are finalized. For the 27th and 28th grants, a total of 3 directors and 3 auditors, plus 27 employees, were allocated, with 213 and 947 rights respectively; ordinary shares allocated: 21,300 shares and 94,700 shares; per-item issue price is 17,800 yen (178 yen per share).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4584","jir_company_name":"Kidswell Bio\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4584-20260825-01.pdf","jir_short_summary":"Issuance details of new stock acquisition rights are finalized. For the 27th and 28th grants, a total of 3 directors and 3 auditors, plus 27 employees, were allocated, with 213 and 947 rights respectively; ordinary shares allocated: 21,300 shares and 94,700 shares; per-item issue price is 17,800 yen (178 yen per share).","jir_summary":"### Summary of Announcement\nToday, based on the board of directors meeting held on 2026-08-07, the allocation details of the stock-based compensation stock options have been finalized. The 27th grant is allocated to 6 individuals (representative director and auditors) totaling 213 rights, targeting 21,300 ordinary shares. The 28th grant is allocated to 27 employees, totaling 947 rights, with 94,700 shares. The payment amount per right is 17,800 yen, and the total amount will be offset against the corresponding grant consideration.\n\n### Impact and Considerations Going Forward\nThe dilutive effect from the issuance of stock acquisition rights is proportional to the number of rights and the number of shares issued. At the time of grant, the valuation based on the Black\u2013Scholes model is used, and it is stated that the receivable of compensation rights will be offset by the cash payment. This matter is part of compensation design for directors and employees, and while there is no direct short-term impact on performance, it aims to enhance long-term corporate value as an incentive design.","jir_financial_highlights":"Total number of stock acquisition rights: 213 \u500b (Unknown)\nTotal number of stock acquisition rights (27th\/28th): 947 \u500b (Unknown)\nType and number of shares underlying the rights: Common shares 21,300 shares (27th) \/ 94,700 shares (28th) (Unknown)\nPaid-in amount per stock acquisition right: 17,800 \u5186 (Unknown)","jir_category":"","jir_hashtags":"#KidswellBio',, StockAcquisitionRight, #Stock-basedCompensationStockOptions, #ExecutiveAppointments, #EmployeeIncentive","jir_key_figures":"213 \u500b: 27th stock acquisition rights total\n947 \u500b: 28th stock acquisition rights total\n21,300 \u682a: Ordinary shares targeted by the 27th stock acquisition rights\n94,700 \u682a: Ordinary shares targeted by the 28th stock acquisition rights\n17,800 \u5186: Paid-in amount per stock acquisition right","jir_meta_title":"\u3010Kidswell Bio\u3011 Issuance Details of Stock-based Compensation Stock Options\uff5cAugust 2026","jir_meta_description":"Kidswell Bio's stock acquisition rights issuance details have been finalized. 27th grant allocated to directors\/auditors: 213 rights, 21,300 shares. 28th grant allocated to employees: 947 rights, 94,700 shares. Paid-in amount per right: 17,800 yen.","jir_og_title":"\u3010Kidswell Bio\u3011 Stock-based Compensation Stock Options Issuance Finalized\uff5cAugust 2026","jir_og_description":"Stock acquisition rights allocation finalized. 213 rights to directors\/auditors, 947 rights to employees. Paid-in amount per right: 17,800 yen. Note on potential dilution going forward.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58797,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-107037","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n